Loading...
XKRX002720
Market cap75mUSD
Jan 09, Last price  
5,450.00KRW
1D
-0.18%
1Q
0.93%
Jan 2017
45.33%
Name

Kukje Pharma Co Ltd

Chart & Performance

D1W1MN
XKRX:002720 chart
P/E
—
P/S
0.82
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
4.68%
Revenues
135.37b
+6.94%
97,272,857,000103,756,103,000121,637,704,000122,564,775,000131,308,308,000104,857,016,220126,768,060,540120,461,297,420122,426,376,880117,636,991,850120,684,005,940123,310,224,120107,681,163,420111,121,601,010130,394,720,790119,745,568,740126,583,402,930135,372,690,530
Net income
-8.42b
L
6,143,517,0006,224,645,0006,604,140,0006,859,001,0004,313,552,000927,806,000-18,940,084,0002,125,167,000-6,932,106,230-5,942,878,860773,061,5501,092,249,3102,192,621,150-4,761,811,9502,203,001,020-1,555,791,2803,557,333,460-8,415,187,456
CFO
3.58b
-45.03%
4,829,648,0009,543,098,0001,072,167,0005,977,556,000-1,550,183,00017,385,055,2901,579,978,970-4,595,893,280-61,109,660-5,080,183,75016,098,588,910786,104,14013,248,711,0703,603,683,0005,099,946,0209,597,051,8106,503,789,1303,575,183,901
Dividend
Dec 27, 201828.571428 KRW/sh

Profile

Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAIDS and other analgesics, gastrointestinal and cardiovascular agents, antidiabetics, genitourinary and respiratory agents, and other ETC products. The company was founded in 1959 and is headquartered in Seongnam, South Korea.
URL
http://www.kukjepharm.co.kr
IPO date
Dec 27, 1975
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
135,372,691
6.94%
126,583,403
5.71%
Cost of revenue
116,325,260
92,872,441
Unusual Expense (Income)
NOPBT
19,047,430
33,710,962
NOPBT Margin
14.07%
26.63%
Operating Taxes
1,734,277
1,202,313
Tax Rate
9.11%
3.57%
NOPAT
17,313,153
32,508,649
Net income
(8,415,187)
-336.56%
3,557,333
-328.65%
Dividends
Dividend yield
Proceeds from repurchase of equity
(31,069)
(40,619)
BB yield
0.03%
0.04%
Debt
Debt current
30,186,343
27,399,949
Long-term debt
1,137,829
2,792,133
Deferred revenue
352,933
296,853
Other long-term liabilities
4,739,425
5,270,507
Net debt
13,492,636
20,669,581
Cash flow
Cash from operating activities
3,575,184
6,503,789
CAPEX
(1,045,895)
(1,276,800)
Cash from investing activities
(1,175,050)
(1,346,899)
Cash from financing activities
2,609,986
(7,473,649)
FCF
3,017,874
33,732,540
Balance
Cash
10,632,154
5,559,106
Long term investments
7,199,382
3,963,395
Excess cash
11,062,901
3,193,331
Stockholders' equity
80,431,393
73,555,327
Invested Capital
109,624,673
103,561,415
ROIC
16.24%
30.99%
ROCE
14.24%
29.40%
EV
Common stock shares outstanding
20,254
20,260
Price
5,920.00
13.02%
5,238.10
-5.94%
Market cap
119,901,282
12.98%
106,125,129
-5.97%
EV
133,399,405
126,799,897
EBITDA
23,251,563
38,198,929
EV/EBITDA
5.74
3.32
Interest
1,439,891
1,000,486
Interest/NOPBT
7.56%
2.97%